Epidemiological study with Phtalox® mouthwash and the clinical relationship of individuals with a diagnosis of COVID-19

Epidemiological study with oral antiseptic Phtalox® and the relationship with the clinical condition of Individuals who present COVID-19 diagnosis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

REBEC

Registry ID

RBR-6c9xnw3

Enrollment

Unknown

Registered

2021-02-05

Start date

2020-11-23

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections

Interventions

The project has a study group: a) Experimental group (n=1.251): The Phthalox solution with active ingredient will be distributed to the entire population, except those under 10 years old, which should

D25.583

Eligibility

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: All inhabitants over 10 years of age who agree to participate in the research residing in the city of Uru-SP

Exclusion criteria

Exclusion criteria: Individuals who do not have clinical conditions to perform mouthwash/gargle daily; individuals who refuse to participate in the research; children under 10 years old

Design outcomes

Primary

Measure	Time frame
It is expected that the Phtalox solution will show a reduction in the incidence of contamination by COVID-19 after being tested in the entire population of the municipality ;The phthalocyanine-containing oral antiseptic is expected to reduce the symptoms of patients positive for COVID-19	—

Secondary

Measure	Time frame
Secondary outcomes are not expected	—

Countries

Brazil

Contacts

Public ContactVerônica Brito Reia

veronicabr@usp.br+55-14-997188391

Outcome results

None listed

Source: REBEC (via WHO ICTRP)